Two studies confirm efficiency of saliva tests for COVID-19
Testing is the cornerstone of the fight against COVID-19, and a test that can be self-administered would greatly increase the options for case...
Could an antidepressant slow COVID-19 progression?
RI-MUHC researchers launch a clinical trial of fluvoxamine, a drug that has already proven efficient in reducing lung injury in animal studies and...
RI-MUHC researcher Nitika Pant Pai advocates improved access to HIV self-testing for Canadians
Canada approves HIV self-testing kit ahead of World AIDS Day 2020
Driving Personalized Medicine: The 2020 RI-MUHC Annual Report is online!
An invitation from Dr. Miguel Burnier Jr.
Paving the way for COVID-19 research
RI-MUHC and McGill Containment level 3 Labs receive $1M in funding to accelerate research with live SARS Cov-2
Two members of the RI-MUHC elected fellows of the Canadian Academy of Health Sciences
Congratulations to Marina Klein and Bernard Robaire!
Spike in peanut and nut anaphylaxis in children at Halloween and Easter
New study suggests education and awareness are needed to help reduce risk of anaphylaxis at specific times of the year
$2M funding to mitigate COVID-19 impact on tuberculosis services
Dr. Madhukar Pai launches studies in India, Indonesia, Nigeria and Peru
Containment Level 3 facilities advance COVID-19 research at the RI-MUHC and McGill
Infrastructure to study COVID-19 in a secure environment is creating new possibilities for collaboration and discovery
From silent infection to rapid death: Why are some people more vulnerable to COVID-19?
Scientists discover genetic and immunological causes of 15 percent of life-threatening COVID-19 cases